Italfarmaco partners with Iktos on Artificial Intelligence to speed drugdiscovery breakthroughs for patients
Combines AI to increase the potential of novel histone deacetylase (HDAC) inhibitors in the non-oncological field
Duchenne Awareness DAY 2023
7 September marks World Duchenne Awareness Day (WDAD), a disease in which we as a company are particularly involved.
Duchenne Awareness DAY 2022
September 7th is World Duchenne Muscular Dystrophy Awareness Day, a disease that sees us, as a company, at the forefront of the search for a drug that can slow down its progression.
Italfarmaco acquires 100% of Lacer, a Spanish pharmaceutical company that is a leader in health care and personal hygiene
Thanks to this operation, that is subject to the approval of the competition authorities, the Group will reach 1,300 employees in Spain and 3,500 globally, with a consolidated turnover of over 1 billion euros.
World Duchenne Awareness Day 2020 – Duchenne and the Brain
World Duchenne Awareness Day represents a great action of the global Duchenne Community to raise awareness for children and young adults living with Duchenne and Becker Muscular Dystrophy. This year the special theme that deserves more attention is “Duchenne and the brain”.
Italfarmaco supports the “Donnenmd” project
"Donnenmd" is a project promoted by the pediatric area of the NeMO Center in Rome, in collaboration with the Agostino Gemelli University Hospital Foundation IRCCS with the aim of providing training and information on some neuromuscular pathologies with childhood onset and to enhance the experiences of affected and caregivers women.
EPICO: EPIgenetic Therapy for the treatment of Coronavirus
As part of the measures to support the development of collaborations for the identification of therapies and diagnostic, protection and analysis systems to combat the Coronavirus emergency and other viral emergencies of the future, the Lombardy Region has financed the project "EPIgenetic Therapy for the treatment of COronavirus infections "- Acronym: EPICO
Identification of new and highly selective inhibitors of histone deacetylase 6
The “Journal of Medicinal Chemistry” publishes a paper on the identification of new and highly selective inhibitors of histone deacetylase 6 (HDAC6) by the Italfarmaco drug discovery team.
Italfarmaco Group is pleased to announce the marketing of GhemaXan, the first biosimilar of Enoxaparin Sodium developed and produced in Italy
Ghemaxan is indicated for the treatment of deep vein thrombosis and pulmonary embolism (except for PE which may require thrombolytic or surgical therapy), serious [...]
Gordon Research Conference on Cancer Genetics and Epigenetics
07-09 April 2019 Dr. Gianluca Fossati, Head of Biochemistry and Molecular Biology at Italfarmaco will present at the forthcoming Gordon Research Conference on Cancer [...]